VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 701 filers reported holding VANECK VECTORS ETF TR in Q2 2021. The put-call ratio across all filers is 1.04 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,472,085 | +34.4% | 54,704 | +50.3% | 0.64% | +32.4% |
| Q2 2023 | $1,095,673 | +6.3% | 36,389 | +14.2% | 0.48% | -3.4% |
| Q1 2023 | $1,030,516 | -1.3% | 31,855 | -12.6% | 0.50% | -10.4% |
| Q4 2022 | $1,044,456 | +19.5% | 36,443 | +0.6% | 0.56% | +21.1% |
| Q3 2022 | $874,000 | -9.9% | 36,237 | +2.3% | 0.46% | -3.8% |
| Q2 2022 | $970,000 | -37.2% | 35,431 | -12.0% | 0.48% | -25.0% |
| Q1 2022 | $1,544,000 | +20.7% | 40,256 | +0.8% | 0.64% | +22.3% |
| Q4 2021 | $1,279,000 | +610.6% | 39,937 | +553.6% | 0.52% | +526.5% |
| Q3 2021 | $180,000 | -13.0% | 6,110 | 0.0% | 0.08% | -23.9% |
| Q2 2021 | $207,000 | -4.6% | 6,110 | +1.0% | 0.11% | -27.3% |
| Q4 2020 | $217,000 | -5.2% | 6,050 | +3.1% | 0.15% | -14.3% |
| Q3 2020 | $229,000 | +6.5% | 5,870 | 0.0% | 0.18% | +1.2% |
| Q2 2020 | $215,000 | +2288.9% | 5,870 | +1799.7% | 0.17% | +2783.3% |
| Q4 2019 | $9,000 | – | 309 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 738,500 | $20,220,000 | 66.82% |
| Baymount Management LP | 145,000 | $3,970,000 | 28.08% |
| New Harbor Financial Group, LLC | 1,371,341 | $37,547,000 | 18.51% |
| New Harbor Financial Group, LLC | 1,291,700 | $35,366,000 | 17.44% |
| MKP Capital Management, L.L.C. | 1,500,000 | $41,070,000 | 13.74% |
| Windmill Hill Asset Management Ltd | 844,600 | $23,125,000 | 11.94% |
| Hollow Brook Wealth Management LLC | 768,567 | $21,043,000 | 11.57% |
| Grand Central Investment Group | 261,915 | $7,171,000 | 10.33% |
| Point72 Europe (London) LLP | 1,467,000 | $40,166,000 | 8.50% |
| Slate Path Capital LP | 4,600,000 | $125,948,000 | 7.87% |